ArticleMolecular biology reports2026
Role of glutamine in promoting the proliferation and chondrogenic differentiation of ATDC5 cells: based on transcriptomic analysis.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundOsteoarthritis (OA) is a commonly occurring degenerative joint disorder. Presently, primary clinical interventions, including nonsteroidal anti-inflammatory drugs (NSAIDs), primarily provide symptomatic alleviation. Glutamine (Gln) has been shown to have protective effects on chondrocytes, which may postpone OA progression. Nevertheless, its effectiveness in the ATDC5 chondrogenic cell line has yet to be explored.
objectiveThe objective of this research was to explore the ability of Gln to increase the proliferation and chondrogenic differentiation of ATDC5 cells and to clarify the underlying molecular mechanisms.
methodsThe murine ATDC5 cell line was maintained in culture, and an in vitro OA model was developed through the application of interleukin-1 beta (IL-1β). The therapeutic effects of Gln were investigated. Cell proliferation was assessed using the CCK-8 assay. The levels of inflammatory mediators and matrix metalloproteinases (MMPs) were measured using Western blot analysis. The expression of chondrogenic markers, including SOX9, aggrecan, and collagen type II (collagen Ⅱ), were also evaluated via Western blotting. A transcriptomic analysis was conducted to identify differentially expressed genes (DEGs) and their related signalling pathways. The crucial molecules involved in these pathways were subsequently validated through Western blot and immunofluorescence techniques.
resultsIn vitro studies revealed that at concentrations of 5 mM, 10 mM, and 20 mM, Gln markedly increased the proliferation of ATDC5 cells, with the effect occurring most strongly at a concentration of 10mM. Notably, Gln concentrations as high as 80mM did not exhibit any cytotoxic effects. Additionally, treatment with 10 mM Gln significantly reduced the expression of inflammatory mediators and matrix metalloproteinases (MMPs) induced by IL-1β. This concentration also promoted the upregulation of key cartilage markers, including aggrecan, collagen II, and SOX9, while significantly decreasing apoptosis in ATDC5 cells. These protective effects appear to be linked to the inhibition of the PI3K-AKT signalling pathway.
conclusionGlutamine alleviates cell injury induced by interleukin-1 beta (IL-1β) by suppressing apoptosis, extracellular matrix breakdown, and inflammatory reactions in ATDC5 cells. Moreover, Gln enhances cell proliferation and promotes chondrogenic differentiation. The observed therapeutic effects seem to operate through the downregulation of the PI3K-AKGT signalling pathway.
Indexed as
Identifiers
41817847What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.